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In an effort to identify the consequences of complete DICER1 loss in tumorigenesis, in this issue of
Cancer Cell, Ravi et al. characterize the effects of homozygous deletion of Dicer1. Using an in vivo mouse
model, they show that genetic deletion of Dicer1 does not preclude tumor formation.MicroRNAs (miRNAs) are small non-
coding RNAs that inhibit gene expression
at the posttranscriptional level. miRNAs
are synthesized in the nucleus by RNA
polymerase II as long primary transcripts,
termed primary miRNAs (pri-miRNAs).
They are subsequently cleaved by
DROSHA to release hairpin-shaped pre-
cursors of 70–90 nucleotides (nt) in length
(pre-miRNAs). These are transported by
Ran-GTP/EXPORTIN-5 (XPO5) to the
cytoplasm, where DICER1 processes
them to yield a 19–22 nt-long duplex.
One strand of the duplex is loaded into
the RNA-induced silencing complex
(RISC), which delivers mature miRNAs to
their mRNA targets. TARBP2, an RNA-
binding protein that forms a complex
with DICER, acts as a biosensor selecting
the miRNA to be loaded into the RISC
complex. It has been predicted that miR-
NAs regulate the translation rate of about
half of all protein-coding genes, so their
role in most biological processes, includ-
ing development, metabolism, cell prolif-
eration, differentiation, and apoptosis,
is now well-recognized. For this reason,
it is not surprising that deregulation of
miRNA levels has been associated with
tumorigenesis.
Although both tumor suppressor and
oncogenic miRNAs have been described,
the global downregulation of miRNAs
is emerging as a common hallmark of
cancer. Recent studies have highlighted
possible mechanisms, including epige-
netic and genetic events, which could
explain this decrease in miRNAs in
tumors. In the same way as previously
described for protein-coding genes, sev-
eral studies have identified CpG island
promoter hypermethylation-associatedepigenetic silencing as a common mech-
anism for miRNA repression in cancer
(Saito et al., 2006; Lujambio et al., 2007;
Davalos et al., 2012).
On the other hand, tumor-specific
genetic defects in genes encoding mem-
bers of themiRNA-processingmachinery,
such as TARBP2, XPO5, and DICER1,
have been described. Truncating muta-
tions in TARBP2, associated with destabi-
lization of the DICER1 protein and conse-
quent impairment of miRNA processing,
have been identified in sporadic and
hereditary carcinomas with microsatellite
instability (MSI) (Melo et al., 2009). Also,
in a subset of human tumors with MSI,
XPO5-inactivating mutations that cause
trapping of pre-miRNAs in the nucleus
and impair the production of mature
miRNAs have been detected in cancer
cells (Melo et al., 2010). In the case of
DICER1, heterozygous germline trun-
cating mutations have been identified
in families with the pleuropulmonary
blastoma-inherited cancer syndrome (Hill
et al., 2009) and hypomorphic somatic
missense mutations have been detected
in non-epithelial ovarian tumors (Heravi-
Moussavi et al., 2012). However, the
complete loss of DICER1 has not been
reported. This fact and evidence from
mouse models have led to the suggestion
that total DICER1 depletion could be
deleterious to tumor development.
In an effort to identify the conse-
quences of complete DICER1 loss in
tumorigenesis, Ravi et al. (2012 [in this
issue of Cancer Cell]) characterize the
effects of homozygous deletion of Dicer1
using two cellular models:Dicer1 null cells
derived from a mouse sarcoma and those
established from murine mesenchymalCancer Cellstem cells (MSCs) (Figure 1). To ensure
accurate assessment, while preventing
competition from cells that retain Dicer1,
clonal isolation of Dicer1/ cells was
compulsory in both cases, since pre-
ferential outgrowth of heterozygous
DICER1-expressing cells was detected
after multiple passages. In comparison
with parental heterozygous Dicerf/- cells,
monoclonal homozygous Dicer1/ cells
derived from both models exhibited a
global loss of mature miRNAs, a concom-
itant accumulation of precursors, dere-
pression of miRNA luciferase reporters,
proliferative lag, delayed exit from G1
phase of the cell cycle, and higher levels
of basal apoptosis.
Having confirmed the tolerance of
Dicer1 depletion in vitro, to address the
main issue at hand—the role of DICER1
in tumorigenesis—Ravi and coworkers
developed an in vivo mouse model.
Dicer1/ sarcoma cells were injected
into both immune-compromised and
immunocompetent mice. In view of the
growth disadvantage of Dicer1 null cells
relative to those retaining Dicer1 expres-
sion detected in vitro, the authors accu-
rately confirmed that the tumors were
composed predominantly of Dicer1/
cells. Strikingly, the experiments revealed
that genetic ablation of DICER1 impaired
but did not preclude tumor formation.
Dicer1/ sarcoma cells did retain their
in vivo tumorigenicity, albeit at lower rates
than Dicer1f/-.
Considering previous publications and
the apparently contrasting results ob-
tained from other mouse models, one of
the main findings of this study is the
detection of the selective growth advan-
tage of Dicer1-expressing cells over21, June 12, 2012 ª2012 Elsevier Inc. 717
Figure 1. Characterization of the Effects of Homozygous Deletion of Dicer1 Using a Murine Sarcoma Model
Dicer1-heterozygous sarcoma tumors were generated after hindlimb injection of Adeno-cre virus inKrasLSL-G12D/+;Trp53f/f;Dicer1f/fmice. Sarcoma cell lines were
established and clones were isolated following Cre-ER integration and tamoxifen treatment. In comparison with parental heterozygous Dicerf/- cells, monoclonal
homozygousDicer1/ cells exhibited a global loss of maturemiRNAswith concomitant accumulation of precursors, proliferative lag, delayed exit fromG1 phase
of the cell cycle, and higher levels of basal apoptosis. Next, Dicerf/- or Dicer1/ sarcoma cells were injected in the flanks of immunocompromised and immu-
nocompetent mice. Although at slower rates relative to Dicer1f/-, Dicer1/ sarcoma cells retained their tumorigenicity in vivo.
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our knowledge about DICER1’s role in
cancer has been achieved through the
use of clonally isolated Dicer1/ cells in
the experiments described in this study.
Thus, the interpretations of previous
results, including those involving analyses
of tumor samples, should be reconsid-
ered since it is possible that subpopula-
tions exist with different proliferative rates
and because of the preferential outgrowth
of cells expressing Dicer1. Ravi et al.
(2012) present convincing evidence that
Dicer1/ cells are able to survive, prolif-
erate without recovery of miRNA process-
ing, and form tumors in mice. However,
the occurrence of homozygous mutations
in nature remains to be demonstrated, so
the conclusions drawn from Dicer1/
models must be considered cautiously.
In addition, the experiments of Ravi
et al. (2012) are limited to mesenchymal
settings (sarcoma and MSCs), so their718 Cancer Cell 21, June 12, 2012 ª2012 Elsconfirmation in other cell models is imper-
ative, especially given the epithelial origin
of most human tumors.
Certainly, however, the experimental
models developed by Ravi et al. (2012)
are a valuable tool for expanding our
knowledge about the function of the
miRNA processing pathway in the context
of cancer. Consistent with previous find-
ings from other genes of the miRNA
pathway that show cancer-related loss-
of-function mutations (Melo et al., 2009,
2010), as well as the well-recognized
global downregulation of miRNAs in
tumors, this study firmly supports the
tumor suppressor role of the miRNA
machinery. In this scenario, restoration of
normalmiRNA levels represents an attrac-
tive approach in cancer therapy. A new
‘‘miRNAome-based’’ strategy has been
suggested, involving the use of the small
molecule enoxacin. Proof-of-principle
studies in human cancer cell lines andevier Inc.xenografted primary tumors have shown
the powerful cancer-specific growth-
inhibitory effect of this drug, mediated by
the TARBP2-dependent restoration of the
expression of tumor suppressor miRNAs
(Melo et al., 2011). The global activation
of miRNA processing by DICER1 stabili-
zation with enoxacin has also been con-
firmed in neurons (Huang et al., 2012). The
tumor suppressor role of miRNAs them-
selves and genes encoding members of
the miRNA processing machinery war-
rants intensive research addressing the
pharmacological approaches required to
restore the global miRNAome in cancer.REFERENCES
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Recently reporting in Nature, Barber et al. demonstrated that SIRT7 maintains critical features that define
cancer cells by removing the acetylation mark on lysine 18 of histone H3. Interestingly, hypoacetylation of
H3K18 has been described as a general marker of tumor prognosis and oncoviral transformation.Sirtuins are NAD+-dependent deacety-
lases that target histone and non-histone
proteins and are major factors in the
response to oxidative, metabolic, and
genotoxic stresses. Their responses are
global and occur at many different levels;
consequently, Sirtuins are at the cross-
roads among the foremost pathways
that control cellular fate, including those
for survival, genomic stability, apoptosis,
and energy or metabolic adaptation. The
importance of Sirtuins is reflected by
their implication in several major human
pathologies, including cancer, diabetes,
cardiovascular diseases and neurode-
generative diseases (Bosch-Presegue´
and Vaquero, 2011).
Mammals have seven Sirtuins (denoted
SIRT1–7) that have considerably different
functions and catalytic activities. SIRT7
has been one of the most puzzling
Sirtuins. Although researchers had clearly
identified SIRT7 in chromatin, they had
not found any clear catalytic activity or
target specificity for it. The only target
that had been proposed for SIRT7 was
p53, but this is currently under debate.
Evidence has supported a crucial rolefor SIRT7 in oxidative and genotoxic
stress response. Homozygous knockout
of Sirt7 in mice causes diminished life-
span and leads to heart hypertrophy
and inflammatory cardiopathy. Cardio-
myocytes derived from these mice show
increased apoptosis as well as hyper-
sensitivity to oxidative and genotoxic
stress. However, other than an ill-defined
functional relationship between SIRT7
and p53 activity, no clear molecular ex-
planation has been determined for these
phenomena (Vakhrusheva et al., 2008b).
Another reported role for SIRT7 is in
the control of ribosomal RNA (rRNA)
expression. SIRT7 localizes mainly in the
nucleolus, where it binds to the rRNA
genes (rDNA) and participates in activa-
tion of RNA-polymerase I (pol-I) transcrip-
tion (Figure 1A). Although this function
apparently depends on SIRT7 having an
intact ‘‘catalytic domain’’ (defined by
homology to other Sirtuins), no mecha-
nism has been described (Ford et al.,
2006). However, some evidence suggests
that this SIRT7 function may be specific
to certain cell types (Vakhrusheva et al.,
2008b; Barber et al., 2012). Interestingly,SIRT7 is relevant for the reactivation of
rDNA transcription at the end of mitosis.
Although the exact mechanism of SIRT7
action here is unknown, its interactions
with the poI-I cofactors UBF and chro-
matin remodeling complex B-WICH have
been described (Grob et al., 2009). Based
on these findings and that SIRT7 is more
abundant in highly proliferative tissues
than in lowly proliferative tissues, a role
for SIRT7 as a principal activator of prolif-
eration has been proposed. On the
contrary, other findings have suggested
that SIRT7 may inhibit proliferation (Ford
et al., 2006; Vakhrusheva et al., 2008a).
This discrepancy has been a subject of
controversy until now.
A recent report in Nature by Barber
et al. (2012) represents a major break-
through in SIRT7 research and redefines
our view on the role of Sirtuins in cancer.
The authors discovered a specific target
of SIRT7 and identified a crucial role for
SIRT7 in the maintenance of cancer
phenotype and transformation. They
found that SIRT7 is specific for a single
histone mark, acetylated lysine 18 in
histone H3 (H3K18Ac), directly linked to21, June 12, 2012 ª2012 Elsevier Inc. 719
